ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.
Kempf, D.J., Marsh, K.C., Denissen, J.F., McDonald, E., Vasavanonda, S., Flentge, C.A., Green, B.E., Fino, L., Park, C.H., Kong, X.P.(1995) Proc Natl Acad Sci U S A 92: 2484-2488
- PubMed: 7708670 
- DOI: 10.1073/pnas.92.7.2484
- Primary Citation of Related Structures:  
1HXW - PubMed Abstract: 
Examination of the structural basis for antiviral activity, oral pharmacokinetics, and hepatic metabolism among a series of symmetry-based inhibitors of the human immunodeficiency virus (HIV) protease led to the discovery of ABT-538, a promising experimental drug for the therapeutic intervention in acquired immunodeficiency syndrome (AIDS) ...